Page 51 - BPOM Terbitkan EUA Vaksin Indovac dan Vaksin AWcorna

The number of computerized platform-based vaccine producers is also still limited in the
world that include Pfizer and Moderna vaccines from the United States.

"The important aspect that should be considered, especially by distributors and health service
facility parties, is the storage process for the AWcorna vaccine," Lukito highlighted.

AWcorna has an advantage over other vaccines with a similar platform since the facilities
that can store at the temperature required for AWcorna are available in almost all regions.

Meanwhile, other vaccines require cold chain storage facilities at a very low temperature of
almost 70 degrees Celsius or lower that are still limited in number in Indonesia.

AWcorna has met the safety, efficacy or immunogenicity, and quality aspects and complied
with the principle of Good Manufacturing Practice (GMP), Lukito stated

AWcorna had been approved to receive EUA for indication of prevention of the SARS CoV-
2 virus infection for individuals aged 18 years and above.

The dosage for primary vaccination is 15μg per dose administered as two injections at an
interval of 28 days.

As a heterologous booster vaccine, AWcorna is administered in a single dose of 15 μg after
six months of the primary vaccination's second dose that utilizes the inactivated vaccine of
Sinovac or Sinopharm.

Based on the clinical trial result, the efficacy of AWcorna vaccine toward the wild type, or
COVID-19 that has not mutated, is 83.58 percent, she noted.

Meanwhile, the COVID-19 vaccine effectiveness of AWcorna against the Omicron variant is
71.17 percent in preventing moderate cases.

"The safety of the AWcorna vaccine, in general, can be well-tolerated, and the reported side
effects are mild in nature," she added.